Abstract Details

Title A multicentre, double blind, randomised, placebo-controlled, cross over study of levetiracetam in the prophylaxis of ‘Chronic Daily Headache’

Topic

Presentation(s) (-)

Poster/Presentation
Number 001

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Roy G. Beran, MD, FAAN (Liverpool Hopsital)	Dr. Beran has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Beran has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Esai. Dr. Beran has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for somnomed. Dr. Beran has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for CMC Lawyers. Dr. Beran has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Bannisters Lawyers. Dr. Beran has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Victorian Crown prosecution. Dr. Beran has received publishing royalties from a publication relating to health care. Dr. Beran has received publishing royalties from a publication relating to health care.
Victoria Smith	No disclosure on file
Paul J. Spira, MD, MB, BS (Spira Neurology)	No disclosure on file
Elliott Ridgeon	No disclosure on file

��ɫ��